Compare CPB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | TVTX |
|---|---|---|
| Founded | 1869 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.3B |
| IPO Year | 1994 | 2013 |
| Metric | CPB | TVTX |
|---|---|---|
| Price | $19.34 | $52.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 15 |
| Target Price | $20.79 | ★ $75.21 |
| AVG Volume (30 Days) | ★ 7.1M | 1.6M |
| Earning Date | 09-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.16% | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $9,744,000,000.00 | N/A |
| Revenue This Year | N/A | $47.65 |
| Revenue Next Year | N/A | $49.39 |
| P/E Ratio | $14.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.60 | $22.59 |
| 52 Week High | $32.04 | $68.73 |
| Indicator | CPB | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 27.37 |
| Support Level | N/A | $41.75 |
| Resistance Level | $21.31 | $59.93 |
| Average True Range (ATR) | 0.56 | 2.36 |
| MACD | 0.00 | -0.93 |
| Stochastic Oscillator | 38.78 | 5.91 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2026 (July year-end), meals and beverages accounted for 61% of its revenue, while snacks accounted for 39%. Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.